Skip to main content

Table 4 Comparison of treatments and outcomes based on primary site

From: Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)

Characteristics

Total cases

(n = 581)

Small intestine

(n = 162)

Ileocecal region

(n = 231)

Large intestine

(n = 125)

Multiple intestinal involvement

(n = 63)

Treatment*

     

   Chemotherapy

521 (89.7%)

143 (88.3%)

213 (92.2%)

105 (84.0%)

60 (95.2%)

   Surgical resection

289 (49.7%)

74 (45.7%)

148 (64.1%)

49 (39.2%)

18 (28.6%)

   Radiotherapy

56 (9.6%)

21 (13.0%)

18 (7.8%)

13 (10.4%)

4 (6.3%)

Response

     

   Complete response

360 (62.0%)

94 (58.0%)

164 (71.0%)

71 (57.0%)

31 (49.0%)

   Partial response

62 (10.7%)

16 (9.9%)

16 (6.9%)

19 (15.0%)

11 (18.0%)

Outcome

     

   Relapse or Progression

199 (34.3%)

57 (35.2%)

65 (28.1%)

50 (40.0%)

27 (42.9%)

   Dead

152 (26.2%)

44 (27.2%)

47 (20.3%)

36 (28.8%)

25 (39.7%)

Survival

     

   Median OS

Not reached

Not reached

Not reached

140 months

61 months

   5-year OS

67%

65%

72%

67%

55%

   Median PFS

88 months

55 months

115 months

66 months

28 months

   5-year PFS

53%

50%

62%

50%

37%

  1. *Some patients were treated with combined modality such as surgery plus chemotherapy. Thus, the sum of number of each treatment is larger than total number of patients.